Human adenovirus replication in immunocompetent Syrian hamsters can be attenuated with chlorpromazine or cidofovir

Journal of Gene Medicine

Volumn 12, Issue 5, 2010, Pages 435-445

  Diaconu, Iulia ^a,b   Cerullo, Vincenzo ^a,b   Escutenaire, Sophie ^a,b   Kanerva, Anna ^a,b   Bauerschmitz, Gerd J ^a,b,c   Hernandez Alcoceba, Ruben ^d   Pesonen, Sari ^a,b   Hemminki, Akseli ^a,b  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Adenovirus; Chlorpromazine; Cidofovir; Replication

Indexed keywords

ADENOVIRUS VECTOR; CHLORPROMAZINE; CIDOFOVIR; CYTARABINE; LUCIFERASE;

ADOLESCENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER CELL CULTURE; CELL KILLING; CONTROLLED STUDY; GENE TRANSFER; HUMAN; HUMAN ADENOVIRUS; HUMAN CELL; IMMUNE DEFICIENCY; IMMUNOCOMPETENCE; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; ONCOLYTIC VIROTHERAPY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SYRIAN HAMSTER; VIRAL GENE THERAPY; VIRUS REPLICATION;

ADENOVIRIDAE INFECTIONS; ADENOVIRUSES, HUMAN; ANIMALS; BIOLOGICAL TRANSPORT; CELL DEATH; CELL LINE; CELL LINE, TUMOR; CELL NUCLEUS; CHLORPROMAZINE; CRICETINAE; CYTARABINE; CYTOSINE; HUMANS; IMMUNOCOMPETENCE; MESOCRICETUS; NEOPLASMS; ORGAN SPECIFICITY; PHOSPHONIC ACIDS; TRANSDUCTION, GENETIC; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALIA; CRICETINAE; HUMAN ADENOVIRUS; MESOCRICETUS AURATUS;

EID: 77952564306     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1453     Document Type: Article

References (53)

1. Fischer SA. Emerging viruses in transplantation: there is more to infection after transplant than CMV and EBV. Transplantation 2008; 86: 1327-1339.
2. Horwitz MS, Valderrama G, Hatcher V, et al. Characterization of adenovirus isolates from AIDS patients. Ann NY Acad Sci 1984; 437: 161-174. (Pubitemid 16238251)
3. Leen AM, Bollard CM, Myers GD, et al. Adenoviral infections in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2006; 12: 243-251.
4. Claas EC, Schilham MW, de Brouwer CS, et al. Internally controlled real-time PCR monitoring of adenovirus DNA load in serum or plasma of transplant recipients. J Clin Microbiol 2005; 43: 1738-1744.5.
5. Lankester AC, van Tol MJ, Claas EC, et al. Quantification of adenovirus DNA in plasma for management of infection in stem cell graft recipients. Clin Infect Dis 2002; 34: 864-867.
6. Huebner RJ, Rowe WP, Schatten WE, et al. Studies on the use of viruses in the treatment of carcinoma of the cervix. Cancer 1956; 9: 1211-1218.
7. Kelly E, Russell SJ. History of oncolytic viruses: genesis to genetic engineering. Mol Ther 2007; 15: 651-659.
8. Liu TC, Kirn D. Systemic efficacy with oncolytic virus therapeutics: clinical proof-of-concept and future directions. Cancer Res 2007; 67: 429-432.
9. Khuri FR, Nemunaitis J, Ganly I, et al. a controlled trial of intratumoral ONYX-015, a selectively replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer. Nat Med 2000; 6: 879-885.
10. Xia ZJ, Chang JH, Zhang L, et al. [Phase III randomized clinical trial of intratumoral injection of E1B gene-deleted adenovirus (H101) combined with cisplatin-based chemotherapy in treating squamous cell cancer of head and neck or esophagus.]. Ai Zheng 2004; 23: 1666-1670.
11. Yu W, Fang H. Clinical trials with oncolytic adenovirus in China. Curr Cancer Drug Targets 2007; 7: 141-148.
12. Bachtarzi H, Stevenson M, Fisher K. Cancer gene therapy with targeted adenoviruses. Expert Opin Drug Deliv 2008; 5: 1231-1240.
13. Kirn D. Clinical research results with dl1520 (Onyx-015), a replication-selective adenovirus for the treatment of cancer: what have we learned? Gene Ther 2001; 8: 89-98.
14. Guse K, Ranki T, Ala-Opas M, et al. Treatment of metastatic renal cancer with capsid-modified oncolytic adenoviruses. Mol Cancer Ther 2007; 6: 2728-2736.
15. Kanerva A, Zinn KR, Chaudhuri TR, et al. Enhanced therapeutic efficacy for ovarian cancer with a serotype 3 receptor-targeted oncolytic adenovirus. Mol Ther 2003; 8: 449-458.
16. Nicklin SA, Dishart KL, Buening H, et al. Transductional and transcriptional targeting of cancer cells using genetically engineered viral vectors. Cancer Lett 2003; 201: 165-173.
17. Ranki T, Kanerva A, Ristimaki A, et al. A heparan sulfate-targeted conditionally replicative adenovirus, Adk7-Delta24, for the treatment of advanced breast cancer. Gene Ther 2007; 14: 58-67.
18. Sarkioja M, Kanerva A, Salo J, et al. Noninvasive imaging for evaluation of the systemic delivery of capsid-modified adenoviruses in an orthotopic model of advanced lung cancer. Cancer 2006; 107: 1578-1588.
19. Shayakhmetov DM, Li ZY, Ni S, et al. Targeting of adenovirus vectors to tumor cells does not enable efficient transduction of breast cancer metastases. Cancer Res 2002; 62: 1063-1068. (Pubitemid 34160288)
20. Raper SE, Chirmule N, Lee FS, et al. Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer. Mol Genet Metab 2003; 80: 148-158.
21. Brunetti-Pierri N, Palmer DJ, Beaud, et al, et al. Acute toxicity after high-dose systemic injection of helper-dependent adenoviral vectors into nonhuman primates. Hum Gene Ther 2004; 15: 35-46.
22. Hartline CB, Gustin KM, Wan WB, et al. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro. J Infect Dis 2005; 191: 396-399.
23. Kanerva A, Raki M, Ranki T, et al. Chlorpromazine and apigenin reduce adenovirus replication and decrease replication associated toxicity. J Gene Med 2007; 9: 3-9.
24. Toth K, Spencer JF, Dhar D, et al. Hexadecyloxypropyl-cidofovir, CMX001, prevents adenovirus-induced mortality in a permissive, immunosuppressed animal model. Proc Natl Acad Sci USA 2008; 105: 7293-7297.
25. Lehman AF, Kreyenbuhl J, Buchanan RW, et al. The Schizophrenia Patient Outcomes Research Team (PORT): updated treatment recommendations 2003. Schizophr Bull 2004; 30: 193-217.
26. Fiala M, Chow A, Guze LB. Susceptibility of herpesviruses to cytosine arabinoside: standardization of susceptibility test procedure and relative resistance of herpes simplex type 2 strains. Antimicrob Agents Chemother 1972; 1: 354-357.
27. Manome Y, Wen PY, Dong Y, et al. Viral vector transduction of the human deoxycytidine kinase cDNA sensitizes glioma cells to the cytotoxic effects of cytosine arabinoside in vitro and in vivo. Nat Med 1996; 2: 567-573.
28. Lim ST, Fayad L, Tulpule A, et al. A phase I/II trial of pixantrone (BBR2778), methylprednisolone, cisplatin, and cytosine arabinoside (PSHAP) in relapsed/refractory aggressive non-Hodgkin's lymphoma. Leuk Lymphoma 2007; 48: 374-380.
29. Baba M, Mori S, Shigeta S, et al. Selective inhibitory effect of (S)-9-(3-hydroxy-2-phosphonylmethoxypropyl)adenine and 2́-nor-cyclic GMP on adenovirus replication in vitro. Antimicrob Agents Chemother 1987; 31: 337-339. (Pubitemid 17011267)
30. Gordon YJ, Romanowski E, Araullo-Cruz T, et al. Inhibitory effect of (S)-HPMPC (S)-HPMPA, and 2́-nor-cyclic GMP on clinical ocular adenoviral isolates is serotype-dependent in vitro. Antiviral Res 1991; 16: 11-16.
31. de Oliveira CB, Stevenson D, LaBree L, et al. Evaluation of Cidofovir (HPMPC, GS-504) against adenovirus type 5 infection in vitro and in a New Zealand rabbit ocular model. Antiviral Res 1996; 31: 165-172. (Pubitemid 26227998)
32. De Clercq E, Holy A. Acyclic nucleoside phosphonates: a key class of antiviral drugs. Nat Rev Drug Discov 2005; 4: 928-940.
33. Muller WJ, Levin MJ, Shin YK, et al. Clinical and in vitro evaluation of cidofovir for treatment of adenovirus infection in pediatric hematopoietic stem cell transplant recipients. Clin Infect Dis 2005; 41: 1812-1816.
34. Thomas MA, Spencer JF, La Regina MC, et al. Syrian hamster as a permissive immunocompetent animal model for the study of oncolytic adenovirus vectors. Cancer Res 2006; 66: 1270-1276.
35. Bortolanza S, Alzuguren P, Bunuales M, et al. Human adenovirus replicates in immunocompetentmodels of pancreatic cancer in Syrian hamsters. Hum Gene Ther 2007; 18: 681-690.
36. Thomas MA, Spencer JF, Toth K, et al. Immunosuppression enhances oncolytic adenovirus replication and antitumor efficacy in the Syrian hamster model. Mol Ther 2008; 16: 1665-1673.
37. Kanerva A, Mikheeva GV, Krasnykh V, et al. Targeting adenovirus to the serotype 3 receptor increases gene transfer efficiency to ovarian cancer cells. Clin Cancer Res 2002; 8: 275-280. (Pubitemid 34101488)
38. Neofytos D, Ojha A, Mookerjee B, et al. Treatment of adenovirus disease in stem cell transplant recipients with cidofovir. Biol Blood Marrow Transplant 2007; 13: 74-81.
39. Yusuf U, Hale GA, Carr J, et al. Cidofovir for the treatment of adenoviral infection in pediatric hematopoietic stem cell transplant patients. Transplantation 2006; 81: 1398-1404.
40. Kanerva A, Wang M, Bauerschmitz GJ, et al. Gene transfer to ovarian cancer versus normal tissues with fiber-modified adenoviruses. Mol Ther 2002; 5: 695-704.
41. Alvarez-Lafuente R, Garcia-Montojo M, De Las Heras V, et al. Interferon-beta treatment and active replication of the JC virus in relapsing-remitting multiple sclerosis patients. Eur J Neurol 2007; 14: 233-236.
42. Carr AJ, Johnston JD, Semikhodskii AG, et al. Photoperiod differentially regulates circadian oscillators in central and peripheral tissues of the Syrian hamster. Curr Biol 2003; 13: 1543-1548.
43. Bazan-Peregrino M, Carlisle RC, Purdie L, et al. Factors influencing retention of adenovirus within tumours following direct intratumoural injection. Gene Ther 2008; 15: 688-694.
44. Sonabend AM, Ulasov IV, Han Y, et al. Biodistribution of an oncolytic adenovirus after intracranial injection in permissive animals: a comparative study of Syrian hamsters and cotton rats. Cancer Gene Ther 2009; 16: 362-372.
45. Bauerschmitz GJ, Lam JT, Kanerva A, et al. Treatment of ovarian cancer with a tropism modified oncolytic adenovirus. Cancer Res 2002; 62: 1266-1270. (Pubitemid 34407775)
46. Blair GE, Dixon SC, Griffiths SA, et al. Restricted replication of human adenovirus type 5 in mouse cell lines. Virus Res 1989; 14: 339-346.
47. Ying B, Toth K, Spencer JF, et al. INGN 007, an oncolytic adenovirus vector, replicates in Syrian hamsters but not mice: comparison of biodistribution studies. Cancer Gene Ther 2009; 16: 625-637.
48. Toth K, Spencer JF, Tollefson AE, et al. Cotton rat tumor model for the evaluation of oncolytic adenoviruses. Hum Gene Ther 2005; 16: 139-146.
49. Thomas MA, Spencer JF, Wold WS. Use of the Syrian hamster as an animal model for oncolytic adenovirus vectors. Methods Mol Med 2007; 130: 169-183.
50. Lichtenstein DL, Spencer JF, Doronin K, et al. An acute toxicology study with INGN 007, an oncolytic adenovirus vector, in mice and permissive Syrian hamsters; comparisons with wildtype Ad5 and a replication-defective adenovirus vector. Cancer Gene Ther 2009; 16: 644-654.
51. Anderson EJ, Guzman-Cottrill JA, Kletzel M, et al. High-risk adenovirus-infected pediatric allogeneic hematopoietic progenitor cell transplant recipients and preemptive cidofovir therapy. Pediatr Transplant 2008; 12: 219-227.
52. Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8: 151-157.
53. Day RS III, Dimattina M. Photodynamic action of chlorpromazine on adenovirus 5: repairable damage and single strand breaks. Chem Biol Interact 1977; 17: 89-97.